Tempus founders build a drug discovery startup, Pathos AI, with $40M in sight

Kyle LaHucik

Senior Reporter

Executives behind AI and precision medicine startup Tempus are putting together another AI outfit in Chicago focused on oncology drug discovery and development.

Pathos AI …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tempus founders build a drug discovery startup, Pathos AI, with $40M in sight

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

AbbVie finally enters obesity race with $350M upfront for Gubra’s amylin

After Phase 3 depression setback, Neumora pauses two trials to make changes, scraps another

ADCs from a decade-old Singapore biotech find new life with $187M

Novo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new metabolic mechanisms

Protagonist, Takeda's profit sharing deal under spotlight after Phase 3 blood disorder trial win

The perfect storm: Why everything is in place for 2025 to be the year of GxP AI

Tem­pus founders build a drug dis­cov­ery start­up, Pathos AI, with $40M in sight

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Tempus founders build a drug discovery startup, Pathos AI, with $40M in sight